Action
Intravenous platelet aggregation inhibitor, monoclonal antibody directed against the platelet glycoprotein GP IIb-IIIa receptor

Status
US FDA approved as an adjunct to percutaneous coronary intervention (PCI) and in unstable angina patients not responding to conventional medical therapy when PCI is planned within 24 hours. Phase II acute stroke trial initiated 1998, published 3/2000. Phase III trial (AbBEST-II) prematurely stopped in October 2005 due to a high rate of intracranial hemorrhage. Further development in stroke is unknown.

Trial(s)
  = Ongoing
  = Completed

		Abciximab and rt-PA in Acute Ischemic Stroke Treatment
	AbESTT	Abciximab in Emergent Stroke Treatment Trial
	AbESTT-II	A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke
	AbESTT-II	Abciximab in Emergent Stroke Treatment Trial - II
	AHAS1	AHAS1: A pilot trial to determine whether reduced dose intravenous Abciximab achieves optimal platelet inhibition in acute ischemic stroke
		MRI-guided abciximab for ischemic stroke
	ReoPro	Abciximab (ReoPro) in Acute Ischemic Stroke
	ROSIE - CT	ReoPro Retavase Reperfusion of Stroke Safety Study-Imaging Evaluation with Computed Tomography [SPOTRIAS]
	ROSIE	ReoPro Retavase Reperfusion of Stroke Safety Study -- Imaging Evaluation [SPOTRIAS]
		Safety and Efficacy of Intra-arterial Reteplase and Intravenous Abciximab in Patients with Acute Ischemic Stroke

UID: 14